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Abstract
Background: Symptomatic uterine fibroids, due to menorrhagia, pelvic pain, bulk symptoms or 
infertility, are a source of substantial morbidity for reproductive-age women. Comparing 
Treatment Options for Uterine Fibroids (COMPARE-UF) is a multi-site registry study to compare 
Corresponding Author: Wanda Nicholson, MD, MPH, MBA, Professor, Obstetrics and Gynecology, University of North Carolina, 
3027 Old Clinic Building; CB# 7570, Chapel Hill, NC 27599-7570. 
Disclosures: The authors report no conflict(s) of interest.
Condensation
Computable phenotyping algorithms may be an efficient approach for recruitment of women with symptomatic fibroids for 
observational and interventional studies.
Implications and Contributions
Women with symptomatic uterine fibroids can report a myriad of symptoms, including pain, bleeding, infertility and psychosocial 
sequelae. Optimizing fibroid research requires the ability to enroll populations of women with image-confirmed symptomatic uterine 
fibroids. Our objective was to develop an electronic health record (EHR)-based algorithm to identify women with symptomatic uterine 
fibroids for a comparative effectiveness study of medical or surgical treatments on quality of life measures. Using an iterative process 
and text mining techniques, an effective computable phenotype algorithm, comprised of demographics, clinical and laboratory 
characteristics, was developed with reasonable performance. Such algorithms provide a feasible, efficient way to identify populations 




Am J Obstet Gynecol. Author manuscript; available in PMC 2018 August 30.
Published in final edited form as:













the effectiveness of hormonal or surgical fibroid treatments on women’s perceptions of their 
quality of life. Electronic health record (EHR)-based algorithms are able to identify large numbers 
of women with fibroids, but additional work is needed to develop EHR algorithms that can 
identify women with symptomatic fibroids to optimize fibroid research.
Objective: To develop an efficient electronic health record (EHR)-based algorithm that can 
identify women with symptomatic uterine fibroids in a large health care system for recruitment 
into large-scale observational and interventional research in fibroid management.
Study Design: We developed and assessed the accuracy of three algorithms to identify patients 
with symptomatic fibroids using an iterative approach. The data source was the Carolina Data 
Warehouse for Health, a repository for the health system’s EHR data. In addition to ICD-9 
diagnosis and procedure codes and clinical characteristics, text data mining software was used to 
derive information from imaging reports to confirm the presence of uterine fibroids. Results of 
each algorithm were compared with expert manual review to calculate the positive predictive 
values (PPVs) for each algorithm.
Results: Algorithm 1 was composed of the following criteria: i) age 18–54 AND ii) either ≥ 1 
ICD-9 diagnosis codes for uterine fibroids or mention of fibroids using text-mined key words in 
imaging records or documents AND iii) no ICD-9 or CPT codes for hysterectomy and no reported 
history of hysterectomy. The PPV was 47% (95% CI: 39%−56%). Algorithm 2 required i) ≥ 2 
ICD-9 diagnosis codes for fibroids AND positive text mined key words and had a PPV of 65% 
(95% CI: 50%−79%). In Algorithm 3, further refinements included ≥ 2 ICD-9 diagnosis codes for 
fibroids on separate outpatient visit dates, the exclusion of women who had a positive pregnancy 
test within three months of their fibroid-related visit, and exclusion of incidentally detected 
fibroids during prenatal or emergency department visits. Algorithm 3 achieved a PPV of 76% 
(95% CI: 71%−81%).
Conclusion: An EHR-based algorithm is capable of identifying cases of symptomatic uterine 
fibroids with moderate positive predictive value and may be an efficient approach for large-scale 
study recruitment.
Keywords
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INTRODUCTION
While electronic health records (EHRs) were launched initially for improvement and 
transferability of patient care documentation and billing, there has been growing interest 
from hospital leaders, federal agencies, and researchers to maximize use of EHRs for 
clinical research. Recent attention by researchers1,2 and federal funders3 has focused on the 
use of EHRs to speed or enhance participant recruitment, particularly for large pragmatic 
trials that focus on a broad range of diseases or conditions, prospective comparative 
effectiveness studies, and for rare diseases or clinical conditions for which there is limited 
evidence on treatment effectiveness.4
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Uterine fibroids (also referred to as leiomyomas or myomas) are common, benign tumors of 
the uterus, reported in 60%−80% of reproductive-age women.5 The majority of women with 
fibroids are asymptomatic, but about 20% of women can experience menorrhagia, pelvic 
pain, bulk symptoms (i.e. pelvic pressure or genitourinary symptoms) or infertility.6 Fibroid 
symptoms can have a substantial impact on women’s daily activities, reducing their quality 
of life and posing a significant emotional burden.7,8 Despite the prevalence and burden of 
uterine fibroids, there is limited population-based research on the comparative effectiveness 
of medical versus surgical treatments. In response to this knowledge gap of treatment 
effectiveness, the Agency for Healthcare Research and Quality (AHRQ)9 and the Patient-
Centered Outcomes Research Institute (PCORI) issued a report10 and priority agenda for 
comparative effectiveness research in uterine fibroids. Part of this research agenda includes a 
national registry of women with symptomatic uterine fibroids and the conduct of large, 
prospective studies to compare patient-centered outcomes among women undergoing 
medical and surgical treatments.5 The report also highlighted current limitations in using 
administrative data to identify symptomatic patients for registry-based fibroid research and 
women’s population health.
The Comparing Treatments Options for Uterine Fibroids (COMPARE-UF) Study11 is a 
multi-site initiative (Mayo (Rochester), INOVA Health System, Brigham and Women’s, 
University of Mississippi, University of California Fibroid Network, Henry Ford Health 
System, University of Michigan, Department of Defense, and University of North Carolina) 
to develop a national registry of women with symptomatic uterine fibroids and prospectively 
compare the effectiveness of different medical (i.e. hormonal) and surgical treatments on 
women’s perceptions of their quality of life. Conducting a large registry study of women 
with uterine fibroids requires an effective EHR algorithm that can be used reliably to 
identify and classify women with fibroids as symptomatic or asymptomatic for appropriate, 
efficient, and timely registry recruitment and study enrollment.
While prior studies have developed EHR-based algorithms to identify women with image-
confirmed uterine fibroids,12 there has been little effort to develop a computable EHR 
phenotype to identify women with symptomatic fibroids, as demonstrated by documentation 
of bleeding, pain, bulk symptoms or infertility. Our objectives were to: 1) develop and refine 
computable phenotyping algorithms that can efficiently identify symptomatic cases of 
uterine fibroids and 2) assess the performance of each algorithm, as measured by positive 
predictive value (PPV), using manual expert chart review as the basis for establishing true 
positive cases of symptomatic fibroids.1 Parallel to COMPARE-UF, we classified women 
with infertility related to fibroids as being symptomatic. While there are studies that focus 
on conception after fibroid management in women with infertility, there is little data on the 
comparative effectiveness of different surgical treatments on quality of life measures in this 
subgroup of women with fibroids.
MATERIALS AND METHODS
Three EHR-based algorithms were developed and refined to identify women with 
symptomatic uterine fibroids using data from the University of North Carolina Health Care 
System (UNCHCS) from April 4, 2014 to October 1, 2015. The UNCHCS is a large, not-
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for-profit integrated academic health system in central North Carolina and provides care to a 
large, diverse population of patients across socioeconomic strata. The Institutional Review 
Board at the University of North Carolina approved the study. Below, we describe the data 
sources and summarize the steps taken to develop and assess the performance of each 
algorithm.
Data Sources
Two sources of data were utilized from the Carolina Data Warehouse for Health (CDW-H),13 
a central data source containing clinical, laboratory and administrative billing data for 
patients seen within the UNC Healthcare system. Data from UNC EHRs are transferred to 
the CDW-H and updated on a nightly basis. We used the following data sources:
1. Clinical EHR data included demographics (i.e. age), patient problem lists, 
laboratory test results, ultrasound and magnetic resonance imaging reports, 
outpatient and in-patient visits and the type of outpatient visits (e.g. radiology, 
medical or emergency department (ED) visits) and medications. The patient 
problem list included the International Classification of Diseases, Ninth Revision 
Clinical Modification (ICD-9-CM) codes for current and past conditions,
2. Billing data included ICD-9-CM diagnosis codes for uterine fibroids, ICD-9-CM 
procedure codes, and Current Procedural Terminology (CPT) codes for 
outpatient, inpatient, and emergency department visits.
Study Population and Definition of Symptomatic Fibroids.
We used the same inclusion criteria to define the study population as those used for the 
COMPARE-UF study: non-pregnant women, ages 18 to 54, with ultrasound or magnetic 
resonance imaging (MRI) that suggests the presence of one or more fibroids, symptomatic 
uterine fibroids and no history of hysterectomy. Because the purpose of COMPARE-UF is to 
assess outcomes after surgical or medical treatment of fibroids, participants were required to 
have an intact uterus with at least one image-confirmed fibroid. The gold standard diagnostic 
modality for fibroids is gray-scale ultrasound, followed by MRI.14
There are currently no gold standard criteria to define symptomatic fibroids. For this study, 
we considered a patient as having symptomatic fibroids if there was EHR documentation of 
the symptoms of bleeding, pain, bulk symptoms or infertility, all of which are consistent 
with the definition of symptomatic uterine fibroids for inclusion in the COMPARE-UF 
registry.
Algorithm Development
Algorithms were developed in an iterative fashion (Figure 1) using a combination of 
demographic inclusion criteria, ICD-9-CM and CPT codes (Table 1), clinical data, and 
keywords related to fibroids from clinical notes and imaging reports, to identify women with 
symptomatic fibroids. For each of the developed algorithms, keyword searches for “positive” 
or “negative” mention of fibroid-related terms [“fibroid,” “leiomyoma,” or “myomata”] 
within specific reports were made using text-mining techniques. Python coding was used to 
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search for negative text terms defined as negators (e.g. “without evidence,” “no evidence”) 
before each of the key terms.
Validation
Algorithms were validated in an iterative fashion as they were developed using expert review 
of randomly selected subsets of charts. Charts were viewed sequentially by a doctoral level 
researcher (SRH), and an Ob/Gyn clinician researcher with clinical experience in uterine 
fibroids (WN) reviewer. A third clinician reviewer (JH) was available to render a final 
decision if the first two reviewers were unable to reach a consensus on symptom status. 
Women were considered positive for symptomatic fibroids if they met any of the following 
criteria: (i) clinician documentation in the medical record stating that the patient had 
“symptomatic fibroids” or “fibroids causing symptoms” or otherwise described the case with 
definitive language indicating that the patient had fibroid-related symptoms; (ii) current 
fibroids for which medical treatment was being considered or administered or cases in which 
surgical management was being planned; (iii) patient had undergone surgical management or 
additional medical treatment specific to uterine fibroids since the date of the algorithm run.
Algorithm Performance
There are no established thresholds for evaluating the performance of automated algorithms 
for use in population-based research, particularly for case-detection of symptomatic uterine 
fibroids where there is no “gold standard” definition of symptomatic fibroid criteria. Our 
goal was to develop algorithms that were simple, translatable for use in other health care 
systems, and could yield a maximized positive predictive value (PPV). For the purpose of 
this study, PPV represents the probability that women identified as having symptomatic 
uterine fibroids based on the algorithm truly have fibroid-related symptoms as determined by 
the chart review (considered as the true positive), as shown in the equation below:
PPV = Patients with symptomatic uterine fibroids by expert chart reviewPatients identified by EHR‐based algorithms
The Clopper-Pearson method15 was used to calculate confidence intervals for binomial 
proportions. Analyses were conducted using SAS 9.3 (SAS Institute Inc., Cary, NC, USA).
RESULTS
Algorithms
The initial algorithm (Algorithm1) included the following: (i) ages between 18 and 54 AND 
(ii) either at least one ICD-9-CM diagnosis code(s) for uterine fibroids OR ultrasound or 
MRI report with positive mention of fibroids, leiomyoma or myomata using text mining 
AND (iii) no ICD-9-CM or CPT codes for hysterectomy AND no documented surgical 
history of hysterectomy (Figure 1). Algorithm 1 identified 4,342 presumptive cases of 
symptomatic uterine fibroids (Table 2). Review of a subset of 150 EHRs of the presumptive 
cases yielded 71 true cases and a PPV of 47% (95% Confidence Interval: 0.39–0.56). The 
primary reason for the misclassifications was the incidental finding of uterine fibroids during 
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the clinical workup or treatment of other gynecologic conditions (e.g. ovarian cysts, pelvic 
inflammatory disease), pregnancy, or abdominal pain.
Algorithm 2 (Figure 1) was designed to exclude those patients from Algorithm 1 that were 
incidental, asymptomatic fibroids. The inclusion criteria were modified to require that 
patients have (i) 2 or more (rather than 1 or more) ICD-9 diagnosis codes for fibroids AND 
(ii) an imaging report with evidence of fibroids. We thought that women with incidental 
fibroids would not have multiple visits with ICD-9 codes for fibroids. Also, we modified the 
criteria to include women who had visits with an ICD-9 diagnosis of fibroids during the 
specified study period (April 4, 2014 to October 1, 2015), but whose imaging reports 
showing uterine fibroids had occurred up to one year prior to the study period. Our premise 
was that women who were symptomatic would have documentation confirming the presence 
of fibroids over a longer period of time. Algorithm 2 identified 1,174 potential cases of 
symptomatic uterine fibroids. Manual review of a subset of 51 EHRs found that 50 (98%) of 
the 51 records had image reports that confirmed the presence of uterine fibroids. Manual 
chart review yielded 30 true cases of symptomatic uterine fibroids, with a PPV of 65% (95% 
Confidence Interval: 0.5–0.79). Some cases were misclassified due to fibroids identified 
during emergency department visits for non-gynecologic conditions (e.g. trauma) or among 
pregnant women during routine perinatal ultrasound. These women truly had fibroids but 
they were not deemed as “symptomatic” upon expert manual review.
In Algorithm 3, we excluded women with incidental fibroids diagnosed during pregnancy. 
Women who had a positive pregnancy test (laboratory data) within three months of the 
fibroid diagnosis or fibroids detected through prenatal rather than general ultrasound were 
excluded. In an effort to exclude women with incidental fibroids diagnosed at the time of an 
emergency department (ED) visit or other ambulatory visit for a non-gynecologic symptom, 
we required that women have at least two ICD-9 diagnosis codes for fibroids on separate 
visit (non ED visit) dates. For Algorithm 3, 99% of the charts reviewed contained image 
documentation of uterine fibroids. After review of 300 EHRs, Algorithm 3 had a PPV of 
76% (95% CI: 71–81).
DISCUSSION
To the best of our knowledge, this is one of the first efforts to develop a computable 
phenotype to identify women with symptomatic uterine fibroids. Using an iterative process, 
we refined the algorithms to exclude asymptomatic cases, including incidental fibroids 
diagnosed during pregnancy, at the time of clinical evaluation of other gynecologic 
conditions or during non-gynecologic related emergency department evaluations. The final 
computable phenotype had a PPV of 76%. This performance seems acceptable given that 
there is no standard clinical variables or laboratory values for identifying symptomatic 
uterine fibroids. Relying solely on an automated algorithm for symptomatic fibroids may not 
be possible. However, our purpose was not to use the algorithms exclusively, but rather, as a 
first step in identifying women with symptomatic uterine fibroids for screening and potential 
enrollment.
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While EHR-derived algorithms to simply identify cases of uterine fibroids have been 
associated with a sensitivity, specificity and PPV
of over 95%,12 much less is known about the ability of EHR algorithms to discriminate 
between patients who are symptomatic and patients with asymptomatic, incidentally found 
fibroids. Our final algorithm has a PPV of 99% for image-confirmed fibroids (Table 2) that 
is similar to that reported by Feingold-Link and colleagues12 to identify patients with image-
confirmed fibroids in a health system database.
The results of this work can inform the use of EHR data for use in conducting large-scale 
fibroid research studies. From a clinical perspective, the final algorithm is simple and able to 
be easily implemented within a healthcare system for the conduct of large research studies to 
assess long-term health or treatment outcomes. The final computable phenotyping algorithm 
can serve as a practical first step in identifying women who are likely to be symptomatic and 
qualify for recruitment to research registries and intervention studies. From a population 
health perspective, the algorithm can contribute to other on-going methods to identify 
symptomatic patients to assess variations in surgical treatment procedures in patients across 
demographic, socio-economic, and geographical strata.16,17
The prevalence of symptomatic fibroids could have affected the PPV of the final algorithm. 
Patient self-report of fibroid symptoms and the completeness of documentation18 of 
symptoms by the clinician are two factors that may also have affected the PPV. It is possible 
that patients with milder symptoms may not have discussed them with their provider. 
Clinicians may not have clearly documented symptoms if it was not the primary reason for 
the health care visit or alternatively, if symptoms were part of several complaints or 
inaccurately attributed to other co-morbidity.
Strengths of this study include our ability to use a combination of billing and EHR data from 
a large health care system. Data was obtained from a well-established data source warehouse 
in which prior algorithms have been developed to identify a range of disease conditions for 
observational studies and registry recruitment.19 The components of the algorithm are 
simple and able to be applied to other health care systems.
There are several limitations that deserve attention. The analysis is based, in part, on 
administrative billing data that may have coding errors. However, fibroids are a common 
gynecologic problem with diagnosis codes that are used regularly by clinicians. Review of a 
subset of EHRs found that the majority of women with an ICD-9 diagnosis code for fibroids 
had image-confirmed fibroids at chart review. Our study was initiated prior to the 
implementation of ICD-10 codes at our institution. We therefore, maintained a timeframe 
(April 4, 2014 to October 1, 2015) that would maintain consistency in using data which was 
coded using ICD-9 codes. We developed the algorithms within a single academic health 
center which may limit the generalizability of the findings to other academic or community 
health systems. Coding practices within UNCHCS may differ from other academic or 
community health systems. We plan further testing of the algorithm in our own health 
system at different time points and in other health organizations to inform refinements for 
broader use in fibroid research. Finally, we were unable to evaluate algorithm sensitivity and 
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specificity because resource constraints limited our ability to randomly select a new set of 
charts (~300) from the EHR to reapply our algorithm.
CONCLUSIONS
We developed and validated a computable phenotype with a PPV of 76% that can begin to 
identify women with symptomatic uterine fibroids using a combination of clinical and 
billing data and expert chart review. This work represents a first step to identify, via an EHR 
computable phenotype, patients with a highly prevalent condition that is associated with 
substantial morbidity and lower perceived quality of life. Further this approach may help to 
enhance research on the effectiveness of management options, treatment patterns and long-
term outcomes. If EHRs can be used effectively to identify patients with symptomatic 
disease for enrollment into a research registry to evaluate the clinical and quality of life 
outcomes of a surgical or medical treatment, then clinicians and researchers will have a 
powerful tool for designing surveillance systems of population health and patient-centered 
outcomes.
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Computable phenotyping algorithms to identify women with symptomatic uterine fibroids in 
an electronic health record (EHR) database
Algorithm 1. Initial algorithm for the identification of women with symptomatic uterine 
fibroids. CPT= current procedural terminology; Text-mining was used to identify keywords 
(fibroids, leiomyoma) in the imaging and clinical reports. Pt= patient; MRI = magnetic 
resonance imaging; US- pelvic ultrasound.
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Algorithm 2. CPT= current procedural terminology. MRI: magnetic resonance imaging; OB: 
obstetrical; Pt: patient; US: ultrasound.
Algorithm 3. Outpatient visits included outpatient scheduled office visits. ED=emergency 
department; MRI: magnetic resonance imaging; OB: obstetrical; Pt: patient; US: ultrasound.
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Table 1.
List of ICD-9 diagnosis and procedure codes and CPT codes used in the algorithms
Description Code Type Codes


























































ICD- 9 = International Classification of Diseases, Ninth Revision; CPT= Current Procedural Terminology
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